This site is intended for healthcare professionals
Drug news

Amgen, Novartis And Banner Alzheimer's Institute discontinue clinical research program With CNP 520 For Alzheimer's Prevention

Read time: 1 mins
Last updated:15th Jul 2019
Published:12th Jul 2019
Source: Pharmawand

Amgen, Novartis and Banner Alzheimer's Institute announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP 520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer's Prevention Initiative Generation Program.

An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function. The sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk. The Generation Program was designed to research the safety and efficacy of CNP 520 for the prevention or delay of the onset of Alzheimer's disease in people at high risk for developing symptoms based on age and their genetic status. Investigators are being informed of the decision and will be contacting their study participants to discontinue the investigational treatment and discuss next steps, including follow-up appointments as appropriate.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.